Comparative Pharmacology
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus POLYETHYLENE GLYCOL 3350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus POLYETHYLENE GLYCOL 3350.
PLEGISOL IN PLASTIC CONTAINER vs POLYETHYLENE GLYCOL 3350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
Osmotic laxative. Polyethylene glycol 3350 is a non-absorbable polymer that retains water in the colon via hydrogen bonding, increasing stool water content and stimulating defecation.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
17 g (1 capful or packet) dissolved in 4–8 oz (120–240 mL) water, administered orally once daily for constipation; for colonoscopy preparation, 240 g (4 L of solution) ingested at 240 mL every 10–15 minutes.
None Documented
None Documented
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Terminal elimination half-life is 1-2 hours in patients with normal renal function; prolonged in renal impairment, but clinical impact minimal due to primarily fecal elimination.
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Renal: approximately 20% excreted unchanged; Fecal: approximately 80% eliminated unchanged in feces.
Category C
Category C
Osmotic Laxative
Osmotic Laxative